
Quarterly report 2023-Q3
added 11-13-2023
Sientra Revenue 2011-2026 | SIEN
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Sientra
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 80.7 M | 71.2 M | 83.7 M | 68.1 M | 36.5 M | 20.7 M | 38.1 M | 44.7 M | 35.2 M | 10.4 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 83.7 M | 10.4 M | 48.9 M |
Quarterly Revenue Sientra
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.5 M | 23.1 M | - | - | 22.6 M | 21.5 M | 21.4 M | - | 19.6 M | 20.1 M | 18.3 M | 22.6 M | 15.3 M | 9.31 M | 16.9 M | 23.2 M | 22.4 M | 20.5 M | 17.6 M | 19 M | 16.9 M | 17.6 M | 14.7 M | 11.1 M | 9.82 M | 8.17 M | 7.49 M | - | 6.53 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 23.2 M | 6.53 M | 17 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
Electromed
ELMD
|
64 M | $ 25.34 | -2.61 % | $ 214 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 12.98 | -2.99 % | $ 1.75 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.3 | -0.15 % | $ 124 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 1.97 | -5.28 % | $ 1.2 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.64 | 7.43 % | $ 39.8 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 10.17 | -8.21 % | $ 288 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Globus Medical
GMED
|
2.94 B | $ 88.1 | -2.88 % | $ 11.9 B | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Pulmonx Corporation
LUNG
|
90.5 M | $ 1.2 | -2.45 % | $ 48.8 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Orthofix Medical
OFIX
|
822 M | $ 11.47 | -3.69 % | $ 454 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.89 | -5.15 % | $ 1.04 B | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Insulet Corporation
PODD
|
2.71 B | $ 162.26 | -11.27 % | $ 11.4 B | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 14.66 | -3.2 % | $ 344 M | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 10.15 | -3.79 % | $ 364 M | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.03 | -0.96 % | $ 17.4 M | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 2.01 | -6.74 % | $ 5.57 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 35.42 | -3.71 % | $ 1.1 B | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 59.11 | -3.56 % | $ 3.22 B | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 52.89 | -4.0 % | $ 1.55 B | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.33 | -0.47 % | $ 63.7 M | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 83.35 | -1.57 % | $ 2.9 B | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 81.31 | -1.18 % | $ 47.6 B | ||
|
TELA Bio
TELA
|
80.3 M | $ 0.83 | 6.01 % | $ 39 M | ||
|
Tandem Diabetes Care
TNDM
|
290 M | $ 17.72 | -4.88 % | $ 1.21 B | ||
|
Tactile Systems Technology
TCMD
|
330 M | $ 22.41 | -4.92 % | $ 513 M | ||
|
Stryker Corporation
SYK
|
7.17 B | $ 312.54 | -2.78 % | $ 119 B |